BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD
January 18, 2018 at 08:13 AM EST
* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY
